Cortex-Based Vaccine Startup Omniose Acquired by AstraZeneca
November 16, 2026
by St. Louis Magazine
Omniose, a St. Louis-based startup developing better ways to make vaccines that fight bacterial infections, has been acquired by the global pharmaceutical and biotech company AstraZeneca.
The two companies made the announcement Tuesday morning, with Omniose becoming a wholly owned subsidiary of AstraZeneca and a part of its Infectious Disease Unit. The announcement did not disclose financial terms.
“The acquisition by AstraZeneca is a great outcome for both organizations. We share a vision for bringing the best science and talent together to address serious bacterial infections, which are increasingly complicated by antimicrobial resistance,” Timothy Cooke, Omniose’s former CEO said in a press release.
It’s a move that comes at the end of a three-year exclusive research collaboration between the two companies.
More Articles
Furniture Firm Relocates to Cortex District
CI Select has moved into the Carriage Works building at 3960 Laclede.
Cortex-Based Vaccine Startup Omniose Acquired by...
Omniose was founded to commercialize new ways of making vaccines against infections caused by bacteria.
We Are Cortex Event Spotlights Local Researchers...
Cortex held its annual celebration of its community of innovators on Wednesday, November 4th.